Getting old in the desired gender: a systematic review on aging diseases in transgender people.
Aging
Gender incongruence
Older adults
Transgender
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
received:
11
12
2023
accepted:
28
02
2024
medline:
21
6
2024
pubmed:
21
6
2024
entrez:
21
6
2024
Statut:
aheadofprint
Résumé
The growing demographic presence of the transgender (TGD) population has sparked an increase in clinical investigations focusing on the impacts of gender-affirming hormone therapy (GAHT) in adults with gender dysphoria. Despite this surge in studies, there remains a significant gap in the literature regarding the health status of older TGD individuals. This review aims to assess prevalent pathological conditions within the TGD population, specifically concentrating on aging-related diseases investigated to date. A systematic search across Embase Ovid, Scopus, PubMed, Cochrane Library, and Web of Science databases was conducted to identify articles reporting on the aging process in TGD individuals. Methodological quality was evaluated using Newcastle-Ottawa Scale (NOS) scores. Initial database searches yielded 12,688 studies, which were refined to 18 through elimination of duplicates and title/abstract review. Following a comprehensive appraisal, nine studies were included in the systematic review. These articles, published between 2017 and 2023, involved a total of 5403 participants. The evidence indicates a noteworthy percentage of the TGD population being at risk for cardiovascular diseases, experiencing depression or disability, and demonstrating hesitancy toward major recommended screening programs. Limited studies on older TGD individuals highlight not only an organic risk of chronic diseases but also a cognitive/psychiatric risk that should not be underestimated. Further research is imperative to deepen our understanding of the pathophysiological mechanisms involved in the health challenges faced by older TGD individuals.
Identifiants
pubmed: 38904914
doi: 10.1007/s40618-024-02353-y
pii: 10.1007/s40618-024-02353-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Coleman E, Radix AE, Bouman WP, Brown GR, de Vries ALC et al (2022) Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health 23(Suppl 1):S1–S259. https://doi.org/10.1080/26895269.2022.2100644
doi: 10.1080/26895269.2022.2100644
pubmed: 36238954
pmcid: 9553112
Fisher AD, Senofonte G, Cocchetti C, Guercio G, Lingiardi V et al (2022) SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people. J Endocrinol Invest 45(3):657–673. https://doi.org/10.1007/s40618-021-01694-2 . (Epub 2021 Oct 22)
doi: 10.1007/s40618-021-01694-2
pubmed: 34677807
Van Caenegem E, Wierckx K, Taes Y, Schreiner T, Vandewalle S, Toye K, Kaufman JM, T’Sjoen G (2015) Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos Int 26(1):35–47. https://doi.org/10.1007/s00198-014-2805-3 . (Epub 2014 Nov 7)
doi: 10.1007/s00198-014-2805-3
pubmed: 25377496
Porcelli T, Maffezzoni F, Pezzaioli LC, Delbarba A, Cappelli C, Ferlin A (2020) Management of endocrine disease: male osteoporosis: diagnosis and management—should the treatment and the target be the same as for female osteoporosis? Eur J Endocrinol 183(3):R75–R93. https://doi.org/10.1530/EJE-20-0034
doi: 10.1530/EJE-20-0034
pubmed: 32544873
Safer JD, Tangpricha V (2019) Care of transgender persons. N Engl J Med 381(25):2451–2460. https://doi.org/10.1056/NEJMcp1903650
doi: 10.1056/NEJMcp1903650
pubmed: 31851801
Wiepjes CM, de Jongh RT, de Blok CJ, Vlot MC, Lips P, Twisk JW, den Heijer M (2019) Bone safety during the first ten years of gender-affirming hormonal treatment in transwomen and transmen. J Bone Miner Res 34(3):447–454. https://doi.org/10.1002/jbmr.3612 . (Epub 2018 Dec 7)
doi: 10.1002/jbmr.3612
pubmed: 30537188
Dziechciaż M, Filip R (2014) Biological psychological and social determinants of old age: bio-psycho-social aspects of human aging. Ann Agric Environ Med 21(4):835–838. https://doi.org/10.5604/12321966.1129943
doi: 10.5604/12321966.1129943
pubmed: 25528930
Hägg S, Jylhävä J (2021) Sex differences in biological aging with a focus on human studies. Elife 13(10):e63425. https://doi.org/10.7554/eLife.63425
doi: 10.7554/eLife.63425
Gamble RM, Taylor SS, Huggins AD, Ehrenfeld JM (2020) Trans-specific Geriatric Health Assessment (TGHA): an inclusive clinical guideline for the geriatric transgender patient in a primary care setting. Maturitas 132:70–75. https://doi.org/10.1016/j.maturitas.2019.12.005 . (Epub 2019 Dec 6)
doi: 10.1016/j.maturitas.2019.12.005
pubmed: 31883667
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29(372):n71. https://doi.org/10.1136/bmj.n71.PMID:33782057;PMCID:PMC8005924
doi: 10.1136/bmj.n71.PMID:33782057;PMCID:PMC8005924
Fredriksen-Goldsen KI, Bryan AE, Jen S, Goldsen J, Kim HJ, Muraco A (2017) The unfolding of LGBT lives: key events associated with health and well-being in later life. Gerontologist 57(suppl 1):S15–S29. https://doi.org/10.1093/geront/gnw185
doi: 10.1093/geront/gnw185
pubmed: 28087792
pmcid: 5241757
Hoy-Ellis CP, Fredriksen-Goldsen KI, Kim HJ (2022) Utilization of recommended preventive health screenings between transgender and cisgender older adults in sexual and gender minority communities. J Aging Health 34(6–8):844–857. https://doi.org/10.1177/08982643211068557
doi: 10.1177/08982643211068557
pubmed: 35112914
pmcid: 9706779
Jung HH, Kim HJ, Fredriksen-Goldsen K (2023) Identifying latent patterns and predictors of health behaviors and healthcare barriers among LGBT older adults. Prev Sci 24(6):1115–1127. https://doi.org/10.1007/s11121-023-01494-5 . (Epub 2023 Feb 10)
doi: 10.1007/s11121-023-01494-5
pubmed: 36763229
pmcid: 10412727
Alzahrani T, Nguyen T, Ryan A, Dwairy A, McCaffrey J, Yunus R, Forgione J, Krepp J, Nagy C, Mazhari R, Reiner J (2019) Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes 12(4):e005597. https://doi.org/10.1161/CIRCOUTCOMES.119.005597
doi: 10.1161/CIRCOUTCOMES.119.005597
pubmed: 30950651
Li Y, Fabbre VD, Gaveras E (2023) Authenticated social capital: conceptualising power, resistance and well-being in the lives of transgender older adults. Cult Health Sex 25(3):352–367. https://doi.org/10.1080/13691058.2022.2044519 . (Epub 2022 Mar 2)
doi: 10.1080/13691058.2022.2044519
pubmed: 35235503
Balcerek MI, Nolan BJ, Brownhill A, Wong P, Locke P, Zajac JD, Cheung AS (2021) Feminizing hormone therapy prescription patterns and cardiovascular risk factors in aging transgender individuals in Australia. Front Endocrinol (Lausanne) 13(12):667403. https://doi.org/10.3389/fendo.2021.667403
doi: 10.3389/fendo.2021.667403
Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA et al (2018) Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med 169(4):205–213. https://doi.org/10.7326/M17-2785 . (Epub 2018 Jul 10)
doi: 10.7326/M17-2785
pubmed: 29987313
pmcid: 6636681
Poteat TC, Divsalar S, Streed CG Jr, Feldman JL, Bockting WO, Meyer IH (2021) Cardiovascular disease in a population-based sample of transgender and cisgender adults. Am J Prev Med 61(6):804–811. https://doi.org/10.1016/j.amepre.2021.05.019 . (Epub 2021 Aug 5. Erratum in: Am J Prev Med. 2022 Jul;63(1):149)
doi: 10.1016/j.amepre.2021.05.019
pubmed: 34364725
pmcid: 8608688
Kiran T, Davie S, Singh D, Hranilovic S, Pinto AD, Abramovich A, Lofters A (2019) Cancer screening rates among transgender adults: cross-sectional analysis of primary care data. Can Fam Phys 65(1):e30–e37
Adan M, Scribani M, Tallman N, Wolf-Gould C, Campo-Engelstein L, Gadomski A (2021) Worry and wisdom: a qualitative study of transgender elders’ perspectives on aging. Transgend Health 6(6):332–342. https://doi.org/10.1089/trgh.2020.0098
doi: 10.1089/trgh.2020.0098
pubmed: 34993305
pmcid: 8664103
Fredriksen-Goldsen KI, Cook-Daniels L, Kim HJ, Erosheva EA, Emlet CA, Hoy-Ellis CP, Goldsen J, Muraco A (2014) Physical and mental health of transgender older adults: an at-risk and underserved population. Gerontologist 54(3):488–500. https://doi.org/10.1093/geront/gnt021 . (Epub 2013 Mar 27)
doi: 10.1093/geront/gnt021
pubmed: 23535500
Jackson SS, Brown J, Pfeiffer RM, Shrewsbury D, O’Callaghan S, Berner AM, Gadalla SM, Shiels MS (2023) Analysis of mortality among transgender and gender diverse adults in England. JAMA Netw Open 6(1):e2253687. https://doi.org/10.1001/jamanetworkopen.2022.53687
doi: 10.1001/jamanetworkopen.2022.53687
pubmed: 36716027
pmcid: 9887492
Correro AN 2nd, Nielson KA (2020) A review of minority stress as a risk factor for cognitive decline in lesbian, gay, bisexual, and transgender (LGBT) elders. J Gay Lesbian Mental Health 24(1):2–19. https://doi.org/10.1080/19359705.2019.1644570 . (Epub 2019 Jul 31)
doi: 10.1080/19359705.2019.1644570
Brady B, Zheng L, Kootar S, Anstey KJ (2023) Sex and gender differences in risk scores for dementia and Alzheimer’s disease among cisgender, transgender, and non-binary adults. Alzheimers Dement 1:1. https://doi.org/10.1002/alz.13317
doi: 10.1002/alz.13317
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6):593–602. https://doi.org/10.1001/archpsyc.62.6.593 . (Erratum in: Arch Gen Psychiatry. 2005;62(7):768. Merikangas, Kathleen R [added])
doi: 10.1001/archpsyc.62.6.593
pubmed: 15939837
Zhang G, Devo P, O’Leary VB, Ovsepian SV (2023) Ageing perspective on cognitive outcomes from reproductive hormone adjustments. Heliyon 9(8):e19050. https://doi.org/10.1016/j.heliyon.2023.e19050
doi: 10.1016/j.heliyon.2023.e19050
pubmed: 37664737
pmcid: 10470197
Cheung AS, Nolan BJ, Zwickl S (2023) Transgender health and the impact of aging and menopause. Climacteric 26(3):256–262. https://doi.org/10.1080/13697137.2023.2176217 . (Epub 2023 Apr 3)
doi: 10.1080/13697137.2023.2176217
pubmed: 37011669
Iwamoto SJ, Defreyne J, Kaoutzanis C, Davies RD, Moreau KL, Rothman MS (2023r) Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults. Ther Adv Endocrinol Metab 19(14):20420188231166496. https://doi.org/10.1177/20420188231166494
doi: 10.1177/20420188231166494
Braun H, Nash R, Tangpricha V, Brockman J, Ward K, Goodman M (2017) Cancer in transgender people: evidence and methodological considerations. Epidemiol Rev 39(1):93–107. https://doi.org/10.1093/epirev/mxw003
doi: 10.1093/epirev/mxw003
pubmed: 28486701
pmcid: 5868281
Leone AG, Trapani D, Schabath MB, Safer JD, Scout NFN, Lambertini M, Berardi R, Marsoni S, Perrone F, Cinieri S, Miceli R, Morano F, Pietrantonio F (2023) Cancer in transgender and gender-diverse persons: a review. JAMA Oncol 9(4):556–563. https://doi.org/10.1001/jamaoncol.2022.7173
doi: 10.1001/jamaoncol.2022.7173
pubmed: 36757703
Gooren L, Morgentaler A (2014) Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia 46(10):1156–1160. https://doi.org/10.1111/and.12208 . (Epub 2013 Dec 12)
doi: 10.1111/and.12208
pubmed: 24329588
Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ (2013) Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 10(12):3129–3134. https://doi.org/10.1111/jsm.12319 . (Epub 2013 Sep 9)
doi: 10.1111/jsm.12319
pubmed: 24010586
de Blok CJM, Wiepjes CM, Nota NM, van Engelen K, Adank MA, Dreijerink KMA, Barbé E, Konings IRHM, den Heijer M (2019) Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 14(365):l1652. https://doi.org/10.1136/bmj.l1652
doi: 10.1136/bmj.l1652
Silverberg MJ, Nash R, Becerra-Culqui TA, Cromwell L, Getahun D, Hunkeler E, Lash TL, Millman A, Quinn VP, Robinson B, Roblin D, Slovis J, Tangpricha V, Goodman M (2017) Cohort study of cancer risk among insured transgender people. Ann Epidemiol 27(8):499–501. https://doi.org/10.1016/j.annepidem.2017.07.007 . (Epub 2017 Jul 22)
doi: 10.1016/j.annepidem.2017.07.007
pubmed: 28780974
Crowley F, Mihalopoulos M, Gaglani S, Tewari AK, Tsao CK, Djordjevic M, Kyprianou N, Purohit RS, Lundon DJ (2023) Prostate cancer in transgender women: considerations for screening, diagnosis and management. Br J Cancer 128(2):177–189. https://doi.org/10.1038/s41416-022-01989-y . (Epub 2022 Oct 19)
doi: 10.1038/s41416-022-01989-y
pubmed: 36261584
Van Caenegem E, Taes Y, Wierckx K, Vandewalle S, Toye K, Kaufman JM, Schreiner T, Haraldsen I, T’Sjoen G (2013) Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone 54(1):92–97. https://doi.org/10.1016/j.bone.2013.01.039 . (Epub 2013 Jan 28)
doi: 10.1016/j.bone.2013.01.039
pubmed: 23369987
Ceolin C, Scala A, DallAgnol M, Ziliotto C, Delbarba A et al (2023) Gender Incongruence Interdisciplinary Group (GIIG). Bone health and body composition in transgender adults before gender-affirming hormonal therapy: data from the COMET study. J Endocrinol Invest. https://doi.org/10.1007/s40618-023-02156-7 . (Epub ahead of print)
doi: 10.1007/s40618-023-02156-7
pubmed: 37450195
pmcid: 10859333
Bretherton I, Ghasem-Zadeh A, Leemaqz SY, Seeman E, Wang X, McFarlane T, Spanos C, Grossmann M, Zajac JD, Cheung AS (2022) Bone microarchitecture in transgender adults: A cross-sectional study. J Bone Miner Res 37(4):643–648. https://doi.org/10.1002/jbmr.4497 . (Epub 2022 Jan 22)
doi: 10.1002/jbmr.4497
pubmed: 34981566
Stevenson MO, Tangpricha V (2019) Osteoporosis and bone health in transgender persons. Endocrinol Metab Clin N Am. 48(2):421–427. https://doi.org/10.1016/j.ecl.2019.02.006 . (Epub 2019 Mar 23)
doi: 10.1016/j.ecl.2019.02.006
Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, Davidge-Pitts C, Nippoldt TB, Prokop LJ, Murad MH (2017) Effect of sex steroids on the bone health of transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab 102(11):3904–3913. https://doi.org/10.1210/jc.2017-01642
doi: 10.1210/jc.2017-01642
pubmed: 28945851
Wiepjes CM, de Blok CJ, Staphorsius AS, Nota NM, Vlot MC, de Jongh RT, den Heijer M (2020) Fracture risk in trans women and trans men using long-term gender-affirming hormonal treatment: a nationwide cohort study. J Bone Miner Res 35(1):64–70. https://doi.org/10.1002/jbmr.3862 . (Epub 2019 Oct 7)
doi: 10.1002/jbmr.3862
pubmed: 31487065
Jannini EA, Nappi RE (2018) Couplepause: a new paradigm in treating sexual dysfunction during menopause and andropause. Sex Med Rev 6(3):384–395. https://doi.org/10.1016/j.sxmr.2017.11.002 . (Epub 2018 Jan 19)
doi: 10.1016/j.sxmr.2017.11.002
pubmed: 29371146
Rozenberg S, Nappi RE, Schaudig K, Jannini EA, Giraldi AGE (2023) Couplepause: deconstructing sick menopause and andropause during midlife. J Sex Med 20(11):1270–1273. https://doi.org/10.1093/jsxmed/qdad113
doi: 10.1093/jsxmed/qdad113
pubmed: 37932239